STOCK TITAN
  1. Home
  2. Sec-filings
  3. ORKA
  4. [Form 4] Oruka Therapeutics, Inc. Insider Trading Activity

Oruka Therapeutics (ORKA) CEO awarded new options and stock grant

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Oruka Therapeutics, Inc. reported that Chief Executive Officer and director Lawrence Otto Klein received new equity awards on January 23, 2026. He was granted 306,700 employee stock options with an exercise price of $34.39 per share, covering the right to buy 306,700 shares of common stock, for which he paid $0 at grant. These options vest as to 1/48 of the underlying shares monthly starting January 1, 2026 and expire on January 22, 2036. In addition, he acquired 76,700 shares of common stock at a price of $0, bringing his directly held common stock position to 929,038 shares. That stock grant vests in 1/16 increments on each March 14, June 14, September 14, and December 14, or the prior trading day if needed.

Positive

  • None.

Negative

  • None.
Insider Klein Lawrence Otto
Role Chief Executive Officer
Type Security Shares Price Value
Grant/Award Employee Stock Option (right to buy) 306,700 $0.00 --
Grant/Award Common Stock 76,700 $0.00 --
Holdings After Transaction: Employee Stock Option (right to buy) — 306,700 shares (Direct); Common Stock — 929,038 shares (Direct)
Footnotes (1)
  1. The grant vests as to 1/16 of the shares on each March 14, June 14, September 14 and December 14 (or if not a trading day, the immediately preceding trading day). The option vests as to 1/48 of the underlying shares monthly from January 1, 2026.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Klein Lawrence Otto
(Last) (First) (Middle)
C/O ORUKA THERAPEUTICS, INC.
855 OAK GROVE AVE., SUITE 100
(Street)
MENLO PARK CA 94025
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Oruka Therapeutics, Inc. [ ORKA ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Executive Officer
3. Date of Earliest Transaction (Month/Day/Year)
01/23/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 01/23/2026 A 76,700(1) A $0 929,038 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Employee Stock Option (right to buy) $34.39 01/23/2026 A 306,700 (2) 01/22/2036 Common Stock 306,700 $0 306,700 D
Explanation of Responses:
1. The grant vests as to 1/16 of the shares on each March 14, June 14, September 14 and December 14 (or if not a trading day, the immediately preceding trading day).
2. The option vests as to 1/48 of the underlying shares monthly from January 1, 2026.
/s/ Paul Quinlan, as attorney-in-fact for Lawrence Klein 01/23/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What equity awards did Oruka Therapeutics (ORKA) CEO Lawrence Otto Klein receive?

Lawrence Otto Klein received 306,700 employee stock options with an exercise price of $34.39 per share and a grant of 76,700 shares of common stock, both awarded on January 23, 2026 at a grant price of $0.

How many Oruka Therapeutics (ORKA) shares does the CEO own after this Form 4?

After the reported transaction, Lawrence Otto Klein beneficially owns 929,038 shares of Oruka Therapeutics common stock in direct ownership, according to the filing.

What are the vesting terms for the Oruka Therapeutics (ORKA) CEO stock grant?

The 76,700-share common stock grant vests as to 1/16 of the shares on each March 14, June 14, September 14, and December 14, or the immediately preceding trading day if those dates are not trading days.

How do the Oruka Therapeutics (ORKA) CEO stock options vest?

The 306,700 employee stock options vest as to 1/48 of the underlying shares monthly, starting from January 1, 2026, as described in the footnotes.

What is the exercise price and expiration date of the Oruka Therapeutics (ORKA) CEO options?

The employee stock options granted to Lawrence Otto Klein have an exercise price of $34.39 per share and an expiration date of January 22, 2036, with 306,700 options outstanding following the transaction.

Is the Oruka Therapeutics (ORKA) CEO’s ownership reported as direct or indirect?

The filing reports the CEO’s 929,038 common shares and 306,700 stock options as held in direct (D) ownership, with no separate indirect ownership entity noted.